New Delhi: The drug 2-deoxy-D-glucose (2-DG), developed by the Laboratory of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defense Research and Development Organization (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL) Hyderabad It will be available for Rs 990 per pouch. However, the central and state government will get the medicine at a discounted price.
The Drug Controller General of India (DCGI) approved an anti-covid drug developed by DRDO for emergency use earlier this month.
The Ministry of Defense said after DCGI’s approval, “The test results have shown that it helps in faster recovery of hospitalized patients and reduces oxygen dependence. Patients treated with 2-DG A high ratio of KVID was found to be negative after RT-PCR test. The drug will be of immense benefit to people suffering from COVID-19. ”
The drug comes in the form of powder in a pouch, which is dissolved in water. It accumulates in virus-infected cells and inhibits the growth of the virus by inhibiting viral synthesis and energy production. Its selective accumulation in viral infected cells makes this drug unique.
In particular, this drug comes as a boon for COVID patients who are experiencing severe oxygen dependence and need to be hospitalized.
The drug is expected to save precious lives due to the mechanism of drug handling in infected cells. The Ministry of Defense stated that it also reduces the hospital stay of COVID-19 patients.
The first batch of 2-deoxy-D-glucose or ‘2-DG’ was released by Defense Minister Rajnath Singh and Union Health Minister Dr. Harsh Vardhan on 17 May.
Notably, DRDO also developed the DIPAS-VDx COVID-19 IgG antibody microvale ELISA, an antibody detection-based kit ‘DIPCOVAN’ for sero-monitoring. The DIPCOVAN kit can detect both spikes of SARS-CoV-2 viruses as well as nucleocapsid (S&N) proteins with a high sensitivity of 97 percent and specificity of 99 percent.